BCL2 and non-small cell lung carcinoma: We first performed combination studies of E7107 and the BCL2/BCLxL inhibitor ABT263 (navitoclax, BCLxL Ki ≤ 0.5 nM)34 in MCL1-dependent NSCLC cell lines, showing that combination of two inhibitors led to synergistic cytotoxic effect in a 8 × 8 dose matrix with large excess over the Loewe additivity models (NCIH23 synergy score = 50.8, NCIH2110 synergy score = 50.2, NCIH1568 synergy score = 35.2; Fig. 6a and Supplementary Fig. 10, left panels).